A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD

References

• Nici L, Mammen MJ, Charbek E, et al., Pharmacologic management of chronic obstructive pulmonary disease. an official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 201(9): e56–e69. 2020.
   Google Scholar
• Bourbeau J, Bhutani M, Hernandez P, et al. Canadian Thoracic Society clinical practice guideline on pharmacotherapy in patients with COPD - 2019 update of evidence. Can J Respir Crit Care Sleep Med. 2019;3(4):210–232.
   Google Scholar
• Cheng SL, Lin CH. COPD Guidelines in the Asia-Pacific regions: similarities and differences. Diagnostics (Basel). 2021;11(7):1153.
   Google Scholar
• The Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2022. Available at: https://goldcopd.org/. ( Accessed 2022 Jan 4).
   Google Scholar
• Rogliani P, Matera MG, Facciolo F, et al., Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: synergy of triple combination therapy on human airway smooth muscle ex vivo. Br J Pharmacol. 177(5): 1150–1163. 2020.
   Google Scholar
• Cazzola M, Dahl R. Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD. Chest. 2004;126(1):220–237.
   Google Scholar
• Matera MG, Page CP, Calzetta L, et al., Pharmacology and therapeutics of bronchodilators revisited. Pharmacol Rev. 72(1): 218–252. 2020.
   Google Scholar
• Calzetta L, Matera MG, Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018;40:95–103.
   Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. Interaction between corticosteroids and muscarinic antagonists in human airways. Pulm Pharmacol Ther. 2016;36:1–9.
   Google Scholar
• Calzetta L, Matera MG, Rogliani P, et al. The role of triple therapy in the management of COPD. Expert Rev Clin Pharmacol. 2020;13(8):865–874.
   Google Scholar
• Usmani OS, Hickey AJ, Guranlioglu D, et al. The impact of inhaler device regimen in patients with asthma or COPD. J Allergy Clin Immunol Pract. 2021;9(8):3033–3040.e1.
   Google Scholar
• Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res. 2021;7(2):00 0–2020.
   Google Scholar
• Miravitlles M, Marín A, Huerta A, et al. Estimation of the clinical and economic impact of an improvement in adherence based on the use of once-daily single-inhaler triple therapy in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1643–1654.
   Google Scholar
• Segreti A, Calzetta L, Rogliani P, et al. Umeclidinium for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2014;8(6):665–671.
   Google Scholar
• Matera MG, Capuano A, Cazzola M. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2015;9(1):5–12.
   Google Scholar
• Calzetta L, Rogliani P, Facciolo F, et al. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017;812:147–154.
   Google Scholar
• Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–380.
   Google Scholar
• Brealey N, Gupta A, Renaux J, et al. Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53(9):753–764.
   Google Scholar
• Li Y, Li H, Sheng Y, et al. Pharmacokinetics of single and repeat doses of fluticasone furoate/umeclidinium/vilanterol in healthy Chinese adults. Clin Pharmacol Drug Dev. 2019;8(6):721–733.
   Google Scholar
• Lipson DA, Barnacle H, Birk R, et al., FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 196(4): 438–446. 2017.
   Google Scholar
• Mehta R, Pefani E, Beerahee M, et al. Population pharmacokinetic analysis of fluticasone furoate/umeclidinium/vilanterol via a single inhaler in patients with COPD. J Clin Pharmacol. 2018;58(11):1461–1467.
   Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al., Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 378(18): 1671–1680. 2018.
   Google Scholar
• Bremner PR, Birk R, Brealey N, et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018;19(1):19.
   Google Scholar
• Mehta R, Farrell C, Hayes S, et al. Population pharmacokinetic analysis of fluticasone furoate/umeclidinium bromide/vilanterol in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 2020;59(1):67–79.
   Google Scholar
• Siler TM, Kerwin E, Sousa AR, et al. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med. 2015;109(9):1155–1163.
   Google Scholar
• Panettieri R, Bangalore M, Camargo C, et al. Effect of once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol triple therapy on severe exacerbation rates compared with twice-daily budesonide/formoterol dual therapy in patients with COPD: a post hoc analysis of the FULFIL study (abstract). Chest. 2021;160(4, Supplement):1818A–1821A.
   Google Scholar
• Panettieri R, Bangalore M, Camargo C, et al. Effect of once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol triple therapy on severe exacerbation rates compared with twice-daily budesonide/formoterol dual therapy in patients with COPD and no history of exacerbations: a post hoc analysis of the FULFIL study (abstract). Chest. 2021;160(4, Supplement):A1822–A1825.
   Google Scholar
• Halpin DMG, Birk R, Brealey N, et al. Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Res. 2018;4(2):00119–2017.
   Google Scholar
• Lipson DA, Birk R, Brealey N, et al. 24-hour serial spirometric assessment of once-daily fluticasone furoate/umeclidinium/vilanterol versus twice-daily budesonide/formoterol in patients with COPD: analysis of the FULFIL study. Adv Ther. 2020;37(12):4894–4909.
   Google Scholar
• Tabberer M, Lomas DA, Birk R, et al. Once-daily triple therapy in patients with COPD: patient-reported symptoms and quality of life. Adv Ther. 2018;35(1):56–71.
   Google Scholar
• Naya I, Compton C, Ismaila AS, et al. Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Res. 2018;4(4):00047–2018.
   Google Scholar
• Halpin DMG, Dransfield MT, Han MK, et al. The effect of exacerbation history on outcomes in the IMPACT trial. Eur Respir J. 2020;55(5):1901921.
   Google Scholar
• Mapel DW, Bogart M, Criner GJ, et al. Reduction in emergency department (ED) visits in patients with chronic obstructive pulmonary disease (COPD): analysis of the IMPACT trial (abstract). Am J Respir Crit Care Med. 2021;203:A2242.
   Google Scholar
• Pascoe S, Barnes N, Brusselle G, et al., Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 7(9): 745–756. 2019.
   Google Scholar
• Cazzola M, Puxeddu E, Ora J, et al. Evolving concepts in chronic obstructive pulmonary disease blood-based biomarkers. Mol Diagn Ther. 2019;23(5):603–614.
   Google Scholar
• Singh D, Criner GJ, Dransfield MT, et al. InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. Respir Res. 2021;22(1):130.
   Google Scholar
• Tabberer M, Jones CE, Kilbride S, et al. Single-inhaler triple therapy and health-related quality of life in COPD: the IMPACT study. Adv Ther. 2020;37(9):3775–3790.
   Google Scholar
• Thomashow B, Stiegler M, Criner GJ, et al. Higher COPD assessment test score associated with greater exacerbations risk: a post hoc analysis of the IMPACT trial. Chronic Obstr Pulm Dis. 2022;9(1):68–79.
   Google Scholar
• Hanania NA, Mannino DM, Criner GJ, et al. Effect of age on the Efficacy and safety of once-daily single-inhaler triple-therapy fluticasone furoate/umeclidinium/vilanterol in patients with COPD: a post hoc analysis of the Informing the pathway of COPD treatment trial. Chest. 2021;159(3):985–995.
   Google Scholar
• Suissa S. Inhaled corticosteroid withdrawal in chronic obstructive pulmonary disease: can IMPACT help? Am J Respir Crit Care Med. 2020;202(9):1202–1204.
   Google Scholar
• Han MK, Criner GJ, Dransfield MT, et al. The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. A randomized, double-blind, multicenter clinical trial. Am J Respir Crit Care Med. 2020;202(9):1237–1243.
   Google Scholar
• Dransfield MT, Crim C, Criner GJ, et al. Risk of exacerbation and pneumonia with single-inhaler triple versus dual therapy in IMPACT. Ann Am Thorac Soc. 2021;18(5):788–798.
   Google Scholar
• Day NC, Kumar S, Criner G, et al. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respir Res. 2020;21(1):139.
   Google Scholar
• Han MK, Criner GJ, Dransfield MT, et al., Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. ERJ Open Res. 7(1): 00663–2020. 2021.
   Google Scholar
• Mammen MJ, Carr TF, Criner GJ, et al. All-cause mortality by subgroup in patients with chronic obstructive pulmonary disease: post hoc analysis of the IMPACT trial (abstract). Am J Respir Crit Care Med. 2021;203:A2241.
   Google Scholar
• Mammen MJ, Carr TF, Criner GJ, et al. Risk of all-cause mortality during and after severe exacerbations in patients with chronic obstructive pulmonary disease (COPD): post hoc analysis of the IMPACT trial (abstract). Am J Respir Crit Care Med. 2021;203:A2243.
   Google Scholar
• Wells JM, Bhatt SP, Carr TF, et al. An analysis of the IMPACT trial assessing single-inhaler therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI using a composite adverse event outcome in patients with COPD (abstract). Am J Respir Crit Care Med. 2021;203:A2240.
   Google Scholar
• Lipson DA, Crim C, Criner GJ, et al., Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 201(12): 1508–1516. 2020.
   Google Scholar
• Kato M, Tomii K, Hashimoto K, et al. The IMPACT study - single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: efficacy and safety in a Japanese population. Int J Chron Obstruct Pulmon Dis. 2019;14:2849–2861.
   Google Scholar
• Marín JM, Mateos L, Roldán J, et al. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT. Ther Adv Respir Dis. 2020;14:1753466620963021.
   Google Scholar
• Bourdin A, Criner G, Devouassoux G, et al. InforMing the PAthway of COPD Treatment (IMPACT trial) single-inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol) versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: analysis of the Western Europe and North America regions. Chronic Obstr Pulm Dis. 2021;8(1):76–90.
   Google Scholar
• Zheng J, Zhong N, Wang C, et al. Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial. Curr Med Res Opin. 2021;37(1):145–155.
   Google Scholar
• Bansal S, Anderson M, Anzueto A, et al. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD. NPJ Prim Care Respir Med. 2021;31(1):29.
   Google Scholar
• Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res. 2021;7(2):00950–2020.
   Google Scholar
• Ferguson GT, Brown N, Compton C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020;21(1):131.
   Google Scholar
• Pelaia C, Procopio G, Deodato MR, et al., Real-life clinical and functional effects of fluticasone furoate/umeclidinium/vilanterol-combined triple therapy in patients with chronic obstructive pulmonary disease. Respiration. 100(2): 127–134. 2021.
   Google Scholar
• Mannino D, Bogart M, Germain G, et al. Benefit of prompt versus delayed use of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) following a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2022;100:491–504.
   Google Scholar
• Bogart M, Bangalore M, McMorrow D, et al. Changes in oral corticosteroids utilization in patients with COPD following initiation of FF/UMEC/VI (abstract). Chest. 2021;160(4):A1826.
   Google Scholar
• Bogart M, Ismaila A, Bangalore M, et al. COPD exacerbations in patients switched from multiple-inhaler triple therapy to FF/UMEC/VI (abstract). Chest. 2021;160(4):A1830.
   Google Scholar
• Huang WC, Chen CY, Liao WC, et al. A real world study to assess the effectiveness of switching to once daily closed triple therapy from mono/dual combination or open triple therapy in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;126:1555–1568.
   Google Scholar
• Halpin DMG, Rothnie KJ, Banks V, et al. S27 Are patients with COPD more adherent to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with multiple-inhaler triple therapy in a real-world UK primary care treated population? (abstract). Thorax. 2021;76(Suppl 2):A20–A21.
   Google Scholar
• Ismaila AS, Risebrough N, Schroeder M, et al. Cost-effectiveness of once-daily single-inhaler triple therapy in COPD: the IMPACT trial. Int J Chron Obstruct Pulmon Dis. 2019;14:2681–2695.
   Google Scholar
• Bogart MR, Hopson SD, Shih HC, et al. COPD exacerbation costs in the IMPACT study: a within-trial analysis. Am J Manag Care. 2020;26(5):e150–e154.
   Google Scholar
• Fenwick E, Martin A, Schroeder M, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. ERJ Open Res. 2021;7(1):00480–2020.
   Google Scholar
• Schroeder M, Benjamin N, Atienza L, et al. Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2020;15:1621–1632.
   Google Scholar
• Zhou Y, Long E, Xu Q, et al. Cost-effectiveness analysis of triple combination preparations in the treatment of moderate-to-severe chronic obstructive pulmonary disease. Front Public Health. 2021;9:713258.
   Google Scholar
• Kendall R, Shukla S, Martin A, et al. Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial (abstract). Eur Respir J. 2021;58:OA78.
   Google Scholar
• Grant AC, Walker R, Hamilton M, et al. The ELLIPTA ® dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers. J Aerosol Med Pulm Drug Deliv. 2015;28(6):474–485.
   Google Scholar
• Jones TL, Neville DM, Chauhan AJ. The Ellipta® in asthma and chronic obstructive pulmonary disease: device characteristics and patient acceptability. Ther Deliv. 2018;9(3):169–176.
   Google Scholar
• Sutton L, Baylis LEE, Jain R, et al. Ease and correct use of ELLIPTA by age in patients with asthma and COPD (abstract). Chest. 2018;154(4):745A–746A.
   Google Scholar
• Anonymous. FDA approves trelegy ellipta. Available at: https://www.drugs.com/newdrugs/fda-approves-trelegy-ellipta-fluticasone-furoate-umeclidinium-vilanterol-copd-4598.html. ( Accessed 2022 Jan 14).
   Google Scholar
• Anonymous. Once-daily Trelegy Ellipta gains expanded indication in the US for the treatment of patients with COPD. Available at: https://www.drugs.com/newdrugs/once-daily-trelegy-ellipta-gains-expanded-indication-us-patients-copd-4730.html. ( Accessed 2022 Jan 14).
   Google Scholar
• Anonymous. FDA advisory committee announces recommendation on the inclusion of mortality data in Trelegy Ellipta prescribing information. Available at: https://www.gsk.com/en-gb/media/resource-centre/fda-advisory-committee-announces-recommendation-on-the-inclusion-of-mortality-data-in-trelegy-ellipta-prescribing-information/. ( Accessed 2022 Jan 14).
   Google Scholar
• Anonymous. Trelegy Ellipta EPAR product information. Available at: https://www.ema.europa.eu/en/documents/product-information/trelegy-ellipta-epar-product-information_en.pdf. ( Accessed 2022 Jan 14).
   Google Scholar
• Anonymous. Trelegy Ellipta summary of opinion (post authorisation). Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trelegy-ellipta_en.pdf. ( Accessed 2022 Jan 14).
   Google Scholar
• Cazzola M, Rogliani P, Laitano R, et al. Beyond dual bronchodilation - Triple therapy, when and why. Int J Chron Obstruct Pulmon Dis. 2022;17:165–180.
   Google Scholar
• Cazzola M, Rogliani P, Matera MG. Escalation and de-escalation of therapy in COPD: myths, realities and perspectives. Drugs. 2015;75(14):1575–1585.
   Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545–555.
   Google Scholar
• Short PM, Williamson PA, Elder DHJ, et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest. 2012;141(1):81–86.
   Google Scholar
• Vanfleteren LEGW, Ullman A, Nordenson A, et al. Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box. ERJ Open Res. 2019;5(1):00185–2018.
   Google Scholar
• Bourdin A, Molinari N, Ferguson GT, et al., Efficacy and safety of budesonide/glycopyrronium/formoterol fumarate versus other triple combinations in COPD: a systematic literature review and network meta-analysis. Adv Ther. 38(6): 3089–3112. 2021.
   Google Scholar
• Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51–60.
   Google Scholar
• Beeh KM, Derom E, Echave-Sustaeta J, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study). Int J Chron Obstruct Pulmon Dis. 2016;11:193–205.
   Google Scholar
• Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–469.
   Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–671.
   Google Scholar
• Cazzola M, Celli B. Triple therapy is also effective in real-world when used in chronic obstructive pulmonary disease patients who are frequent exacerbators. Respiration. 2021;100(2):93–950.
   Google Scholar